Rep. Gilbert Ray Cisneros, Jr. Unloads Zoetis Inc. (NYSE:ZTS) Stock

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Zoetis Inc. (NYSE:ZTS). In a filing disclosed on September 04th, the Representative disclosed that they had sold between $1,001 and $15,000 in Zoetis stock on July 17th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Mesabi Trust (NYSE:MSB) on 7/31/2026.
• Purchased $1,001 – $15,000 in shares of Praxis Precision Medicines (NASDAQ:PRAX) on 7/30/2026.
• Purchased $15,001 – $50,000 in shares of Alkermes (NASDAQ:ALKS) on 7/30/2026.
• Sold $15,001 – $50,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 7/30/2026.
• Sold $100,001 – $250,000 in shares of Alibaba Group (NYSE:BABA) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of SailPoint (NASDAQ:SAIL) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Glacier Bancorp (NYSE:GBCI) on 7/21/2026.
• Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 7/21/2026.

Zoetis Stock Down 1.4%

Zoetis stock traded down $1.08 during trading hours on Tuesday, hitting $74.73. The company had a trading volume of 787,326 shares, compared to its average volume of 5,673,565. Zoetis Inc. has a fifty-two week low of $71.00 and a fifty-two week high of $152.12. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The firm has a market capitalization of $30.88 billion, a P/E ratio of 12.30, a price-to-earnings-growth ratio of 1.77 and a beta of 0.73. The firm’s fifty day moving average is $75.58 and its 200-day moving average is $93.26.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same period in the previous year, the company posted $1.76 EPS. Zoetis’s revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.2 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on ZTS shares. Weiss Ratings lowered Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. Piper Sandler lowered their price target on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. JPMorgan Chase & Co. dropped their price objective on Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a research report on Tuesday, August 25th. Finally, Barclays decreased their target price on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $107.43.

Institutional Trading of Zoetis

Several large investors have recently made changes to their positions in ZTS. Prosperity Bancshares Inc acquired a new stake in Zoetis in the 4th quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis in the first quarter worth $28,000. Elyxium Wealth LLC bought a new stake in shares of Zoetis during the 4th quarter worth $32,000. Root Financial Partners LLC boosted its holdings in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after buying an additional 103 shares during the period. Finally, Wellington Grp LLC grew its stake in Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after buying an additional 267 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.